PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of ...

Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson. Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs ...

RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination ...

Fixed-dose combination of nivolumab and relatlimab holds the cancer in check significantly longer than nivolumab alone This is the first regimen to demonstrate a statistical benefit over anti-PD-1 ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that primary endpoint was met in the phase II/III Relativity-047 study, a trial evaluating a fixed dose combination of company's anti-LAG-3 ...

The U.S. Food and Drug Administration has approved a novel therapy for patients with metastatic or inoperable melanoma, an aggressive type of skin cancer. The treatment, developed based on original ...

A dual immunotherapy regimen targeting the novel lymphocyte-activation gene 3 (LAG-3) immune checkpoint led to a significant progression-free survival (PFS) benefit in patients with advanced melanoma, ...

For untreated advanced melanoma, the fixed-dose combination of relatlimab and nivolumab is a "game changer that we have been waiting 10 years for," Hussein Tawbi, MD, PhD, University of Texas MD ...

Please provide your email address to receive an email when new articles are posted on . Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with ...